Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Cesk Farm ; 39(6): 266-74, 1990 Jul.
Artigo em Tcheco | MEDLINE | ID: mdl-1981860

RESUMO

Metazosin (KENOSIN) displaces 3H-prazosin from its bond to alpha-1 receptors of the cerebral cortex, antagonizes the effects of phenylephrin on spinal rats and on perfused peripheral vascular regions, which demonstrates that it is a blocker of alpha-1 adrenergic receptors. It does not affect the central alpha-2 adrenergic receptors. No peripheral antiserotonin effect was found. Metazosin decreases the blood pressure in normotensive and hypertensive animals. On intravenous administration, the decrease commences very rapidly after the onset of administration. In dogs, systolic and diastolic blood pressure, cardiac output, peripheral resistance and pressure in the pulmonary artery are decreased. In animals with experimentally increased pressure in the lesser circulation it produces a decrease in pressure. On the basis of hypotensively active doses in experimental animals, the administration of 5 mg was proposed as the clinica pose. Results of the 1st stage of clinical trials have demonstrated that this dose is effective in persons with the systolic pressure higher than 120 mm Hg. At present the effect of metazosin is tested on hypertonic patients.


Assuntos
Antagonistas Adrenérgicos alfa/farmacologia , Anti-Hipertensivos/farmacologia , Quinazolinas/farmacologia , Antagonistas Adrenérgicos alfa/uso terapêutico , Animais , Anti-Hipertensivos/uso terapêutico , Cães , Hemodinâmica/efeitos dos fármacos , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Masculino , Camundongos , Camundongos Endogâmicos , Quinazolinas/uso terapêutico , Coelhos , Ratos , Ratos Endogâmicos
3.
Cas Lek Cesk ; 129(17): 529-31, 1990 Apr 27.
Artigo em Tcheco | MEDLINE | ID: mdl-2350770

RESUMO

Twenty women with asymptomatic significant bacteriuria took Trimethoprim (TMP) VUFB, 2 X 200 mg, for eight days. Twelve had morphological changes of the urinary pathways confirmed by intravenous pyelography. The test for the presence of bacteria with an antibody film in the urinary sediment suggested that the infection was in the upper urinary pathways in eight of the women. Immediately after termination of treatment the urine was negative in 16 women (80%), after another three weeks the negative finding persisted in the urine of nine women (45%). In one patient treatment was discontinued after five days on account of dyspeptic complaints, the remaining patients tolerated the drug well.


Assuntos
Trimetoprima/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Adolescente , Adulto , Idoso , Bacteriúria , Humanos , Pessoa de Meia-Idade , Infecções Urinárias/urina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...